GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04251117 |
Recruitment Status :
Active, not recruiting
First Posted : January 31, 2020
Last Update Posted : April 19, 2024
|
Sponsor:
Geneos Therapeutics
Information provided by (Responsible Party):
Geneos Therapeutics
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Actual Primary Completion Date : | August 1, 2023 |
Estimated Study Completion Date : | June 2025 |